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Abstract
Cyclin-dependent kinases (CDKs) and their targets have been primarily associated with regulation of cell-cycle progression.
Here we identify c-Jun, a transcription factor involved in the regulation of a broad spectrum of cellular functions, as a newly
recognized CDK substrate. Using immune cells from mouse and human, and several complementary in vitro and in vivo
approaches including dominant negative protein expression, pharmacologic inhibitors, kinase assays and CDK4 deficient
cells, we demonstrate the ability of CDK4 to phosphorylate c-Jun. Additionally, the activity of AP-1, a ubiquitous
transcription factor containing phosphorylated c-Jun as a subunit, was inhibited by abrogating CDK4. Surprisingly, the
regulation of c-Jun phosphorylation by CDK4 occurred in non-dividing cells, indicating that this pathway is utilized for cell
functions that are independent of proliferation. Our studies identify a new substrate for CDK4 and suggest a mechanism by
which CDKs can regulate multiple cellular activation functions, not all of which are directly associated with cell cycle
progression. These findings point to additional roles of CDKs in cell signaling and reveal potential implications for
therapeutic manipulations of this kinase pathway.
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Introduction
Progression of eukaryotic cells through the cell cycle is
controlled by serine/threonine kinases known as Cyclin Depen-
dent Kinases (CDKs). Early studies utilizing cell lines established
the dependence of transition from G0/G1 into the S phase upon
CDK 4, 6, and 2-controlled checkpoints [1]. However, various
CDK-deficient mice are viable, [2,3,4,5] although displaying cell-
type specific abnormalities [4,5,6,7]. Thus, while individual CDKs
are dispensable for mammalian development, they have cell type-
specific functions [7]. These activities include cytoskeletal
rearrangement, anti-apoptotic signaling, cell adhesion and cell
mobility [8,9,10,11]. Whereas the molecular interactions of CDKs
in cell cycle progression are well studied, the mechanisms involved
in these additional roles are currently unknown. It is hypothesized
that the non-proliferative functions mediated by CDKs involve
previously unidentified CDK targets [10].
Stimulation of cells through receptors or via changes in
environmental conditions (e.g. heat, salinity, pH) induces activa-
tion of the stress activated protein kinases (SAPK), including c-Jun
N-terminal Kinase (JNK) [12,13]. JNK activation mediates direct
phosphorylation of its substrate c-Jun [12–14]. Upon phosphor-
ylation, c-Jun forms homo or heterodimers with other AP-1 family
members to form an active AP-1 transcription complex [14]. AP-1
dimers of distinct composition preferentially enhance transcription
of a wide variety of target genes, including other AP-1 family
subunits [15]. Thus, the enhanced production of AP-1 subunits
increases the complexity and consequences of initial AP-1
activation. Initial JNK and c-Jun activities are therefore extremely
important in orchestrating diverse cellular responses. We’ve
previously shown that increased c-Jun phosphorylation does not
always correlate with JNK activity in B lymphocytes, suggesting
that other kinase(s) can regulate c-Jun, and therefore AP-1,
functions [16].
Here we demonstrate that CDK4 directly phosphorylates c-Jun
in B lymphocytes and dendritic cells (DC) independently of cell
proliferation, regulating AP-1 activity and AP-1-regulated cytokine
production. In addition to the discovery of an important new
CDK substrate that broadens the role of CDKs in cellular
function, these findings have implications for potential therapeutic
manipulation of CDK family members [17,18,19].
Results
The effects of CDK inhibitors on phosphorylation of c-Jun
and cyclin D production
Stimulation of B cells through either the innate immune
receptor Toll-like receptor (TLR) 7 or the adaptive immune
costimulator CD40 activates multiple MAPKs, including JNK
[16,20]. Activated JNK phosphorylates and activates the substrate
c-Jun. Active c-Jun then homodimerizes or heterodimerizes with
members of the c-Jun, cFos, or ATF families to form the
transcription factor AP-1 [15,21]. However, in B cells stimulated
through TLR7 and CD40 – together or individually, the activity of
JNK is temporally disconnected from c-Jun phosphorylation with
c-Jun phosphorylation persisting in the absence of detectible active
JNK [16]. Stimulation through both TLR7 and CD40 results in
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19468the most profound separation between JNK activation and c-Jun
phosphorylation (16). Therefore, this dual stimulation was used in
the present studies.
While JNK activation peaked and subsided within 60 minutes of
dual CD40+TLR7 stimulation, the phosphorylation of c-Jun was
first measurable at 30 minutes, continued to increase over 6 hours
and remained elevated for up to 20 hours (Fig. 1). Because active
c-Jun allows formation of the AP-1 transcription factor, which
promotes c-Jun production [15], total c-Jun also increased during
this time, requiring the use of actin as a loading control (Fig. 1).
The continued increase in p-c-Jun levels hours after JNK activity
had diminished suggests that other kinases make important
contributions to the sustained phosphorylation of c-Jun, a
possibility we wished to investigate. Members of the MAPK/
SAPK family such as p38 and ERK were potential candidates as
they also phosphorylate c-Jun [22]. However, the kinetics of p38
and ERK activation in response to dual stimulation via CD40 and
TLR7 were similar to those of JNK (Fig. 1). These results, together
with the relatively large increase in c-Jun phosphorylation seen
beyond 60 minutes, suggested that an additional kinase capable of
phosphorylating c-Jun was active during early TLR7+CD40
signaling events.
Interactions between the JNK signaling pathway and compo-
nents of the cell cycle machinery have been reported [19,23,24].
Specifically, pharmacologic inhibition of CDKs in neurons affects
activity of AP-1 and direct phosphorylation of c-Jun by CDK3 has
been observed in response to erythropoietin receptor signaling in
epithelial cells [23,24]. As phosphorylated c-Jun is a subunit of AP-
1, we hypothesized that CDKs may be involved in the sustained
phosphorylation of c-Jun. Positive regulation of CDK activity
depends upon the expression of small polypeptide co-enzymes
called cyclins [25]. Early proliferative events dependent upon
CDK4 activity, such as the transition of cells from G0/G1 to S
phase, are initiated by de novo expression of cyclinD family members
[26]. Thus, to determine the potential for CDK4 activity during the
initial 8 h of stimulation, activated B cells were analyzed for levels of
cyclin D2 (the predominant cyclin D family member in B cells)
[27,28]. CDK4 was active in as little as 60 minutes following
receptor engagement, as demonstrated by detectable increases in
total cellular cyclin D2 (Fig. 1B). While the presence of cyclin D2
indicates CDK4 activity, the role of its activity in c-Jun
phosphorylation was still unknown. As an additional test of our
hypothesis, the effect of inhibiting CDKs on the phosphorylation of
c-Jun was monitored. Each of two structurally distinct CDK
inhibitors, SU9516 and Fascaplysin, abrogated the accumulation of
phosphorylated c-Jun in stimulated mouse (Fig. 1C) and human B
cells (Fig. 1D). Thus, CDKs emerged as potential candidate kinases
to regulate c-Jun phosphorylation.
Requirement for CDK activity in AP-1 activation and IL-6
production
Pharmacologic kinase inhibitors are useful as detectors of potential
kinase involvement in a pathway, but they rarely display complete
enzyme specificity. SU9516 and Fascaplysin are pan-CDK inhibitors
with selectivity for CDK2 and CDK4 in vitro and in vivo [29,30].
Because the effect on cJun phosphorylation was observed between 0
and 6 hours, we focused on CDK4 due to its relatively early activity
in initiating cell proliferation, and tested the role of CDK4 in c-Jun
phosphorylation using more direct approaches.
Using the easily transfected epithelial cell line 293T [31], we tested
the capacity of a kinase-dead CDK4 mutant molecule (R158N) to
inhibit AP-1 activity. Expression of the kinase dead, dominant
negative CDK4 R159N mutant inhibited TLR-induced AP-1
reporter gene activity in a dose dependent manner (Fig. 2A). Because
Fig. 1. JNK independent cJun phosphorylation. Purified B
lymphocytes were stimulated through both CD40 and TLR7 for
indicated times. Cells were lysed and analyzed by Western blot for A)
phospho–cJun, total -cJun and Actin as a loading control and B) CDK4
and cyclin D2. C) Resting splenic B lymphocyets were stimulated
through TLR7 and CD40 (R848 1 ug/ml and CD40L) for the indicated
times. Cells were lysed and analyzed for phosphorylated MAP kinases
by Western blot. D) Mouse high density splenic B cells or E) human
peripheral B cells were stimulated through both CD40 and TLR7 for the
designated times in the absence or presence of CDK4 inhibitors SU9516
– CDK-I (10 uM) or Fascaplysin (5 uM) for 5 hours. Cells were then lysed
and analyzed for phospho-cJun by Western blot. Results are
representative of .3 separate experiments.
doi:10.1371/journal.pone.0019468.g001
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containing AP-1 [32], we tested the downstream effects of CDK
inhibition first by monitoring IL-6 production as a biologically
relevant effector function. While cell viability was unaffected, the
production of IL-6 was dramatically reduced in mouse B cells treated
with the CDK inhibitor SU9516 (Fig. 2B) and human B cells treated
with the CDK4 specific inhibitor CINK (Fig. 2C).
Effects of cellular proliferative status on CDK4 regulation
of AP-1
The in vitro kinetics of cJun phosphorylation described above
suggest that CDK-mediated c-Jun phosphorylation occurred prior
to cell proliferation. To further explore the possibility that CDK4
regulates c-Jun phosphorylation independent of cellular prolifer-
ation, we examined the role of CDK4 in the ability of terminally
differentiated bone marrow dendritic cells (BMDCs) to produce
IL-6 and phosphorylate c-Jun (fully differentiated BMDCs did not
undergo proliferation in response to TLR stimulation - Fig. 3).
BMDCs stimulated through TLR7 and treated with CDK
inhibitor showed a decrease in c-Jun phosphorylation and a
concomitant decrease in IL-6 production, supporting the concept
that CDKs are utilized in c-Jun/AP-1 signal transduction (Fig. 3A
and B). To corroborate these findings, BMDCs were expanded
from Wt and CDK4
2/2 mice and tested for c-Jun phosphoryla-
tion and cytokine production upon TLR stimulation. Despite
comparable in vitro differentiation and activation, as determined by
CD11c and CD86 expression respectively (Fig. S1), CDK4
2/2
BMDCs produced significantly less IL-6 and IL-12 compared to
WT BMDCs from littermate controls. Interestingly, the level of
TNF-a produced was not significantly different between the two
groups, indicating that different cytokines may have different levels
of dependence upon CDK-regulated c-Jun phosphorylation and
AP-1 activity (Fig. 3C). In addition, the level of phosphorylated c-
Jun was ,30% lower in cells from the CDK4
2/2 mice (Fig. 3D).
Importantly, human myeloid cells displayed similar p- c-Jun and
cytokine production deficiencies when treated with a CDK4
specific inhibitor (Fig. 3E and F).
To further analyze the activity of CDK4 in non-dividing cells,
the phosphorylation of the CDK4 specific target Ser 780 of
Retinoblastoma protein was monitored in a mixed myeloid
population expanded from bone marrow. Phosphorylated Rb
was observed in both dividing (CFSE low) and non-dividing
(CFSE high) populations using flow cytometry, thus demonstrating
that CDK4 can be active in non-dividing cells (Fig. 4).
Effects of TLR7 and CD40 stimulation on CDK4 activation
The CDK4 dependence of cJun phosphorylation could be
explained by either direct interaction or indirect consequences. To
test the possibility of a direct interaction between CDK4 and c-
Jun, purified CDK4/cyclinD complex was tested for its ability to
Fig. 2. Effect of CDK inhibition on AP-1 function. A) 293T cells were transfected with increasing amounts of a plasmid encoding kinase dead
CDK4, together with a construct producing murine TLR7 and an AP-1-luciferase reporter plasmid. Empty pRSV.neo plasmid was added to equalize the
total amount of transfected DNA. After 24 hours of stimulation with the TLR7 agonist R848, relative amounts of luciferase activity were measured. B)
IL-6 production by B cells stimulated with the agonistic anti-mouse CD40 antibody 1C10 and R848 with or without the CDK inhibitor SU9516 was
quantified by IL-6-specific ELISA assay, as described in Methods. C) IL-6 production by purified human peripheral B cells stimulated with R848 for
24 hours with or without the CDK inhibitor SU9516 was monitored by ELISA. These data are each representatives of 3 separate experiments.
doi:10.1371/journal.pone.0019468.g002
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complex phosphorylated c-Jun but was unable to phosphorylate
the control substrate Gsk-a, indicating that the direct c-Jun
phosphorylation was substrate specific (Fig. 5A). To determine if
this interaction occurs upon stimulation of cells, CDK4 was
immunoprecipitated from differentially stimulated B lymphocytes
and incubated with c-Jun -GST fusion proteins in an in vitro kinase
assay. These CDK4 complexes phosphorylated c-Jun (Fig. 5B).
These data, together with previous results suggest that CDK4
phosphorylates c-Jun in vivo. Consistent with early CDK4
activation events, the level of cyclin D2 association with CDK4
was increased upon B cell stimulation, and the level of associated
Fig. 3. Effects of CDK4 inhibition on cytokine production and cJun phosphorylation in non-dividing cells. Differentiated BMDCs were
stimulated with the TLR7 agonist R848 in the presence and absence of CDK-I (SU9516) for 6 and 24 hours and monitored for A) cJun phosphorylation
and B) IL-6 production, as described in Methods. C) As indicated by CFSE staining, matured BMDCs did not proliferate upon TLR7 stimulation – DCs
were either fixed (light grey line) or stimulated with R848 for 48 hours (dark grey line) D) BMDCs from CDK4 deficient mice and CDK4+/+ littermate
controls were stimulated with R848 (1 ug/ml) for 24 hours and supernatants subjected to cytokine multiplex analysis. E) BMDCs from CDK4 deficient
mice and CDK4+/+ were stimulated with R848 (1 ug/ml) for 6 hours and assayed for cJun phosphorylation. The level of c-Jun phosphorylation in the
CDK4 sufficient cells, as determined by the p-c-Jun:actin ratio, was set to 100%. The level of p-c-Jun in CDK4 deficient cells was normalized to the
100%. F) Human monocyte-derived macrophages were stimulated with or without R848 for 6 hours in the presence of medium, DMSO (drug diluent),
or the CDK4-specific inhibitor CINK. Cell lysates were then prepared and analyzed by Western blot for the presence of phospho-cJun. Actin was
measured as a loading control. G) Human monocyte-derived macrophages were stimulated with or without R848 for 24 hours in the presence of
DMSO, or the CDK4-specific inhibitor CINK. Supernatants were collected and analyzed for cytokines using multiplex technology. (*) indicates
statistical significance – P-value ,0.05 using Student t-test. These data are each representative of between 2 and 4 separate experiments.
doi:10.1371/journal.pone.0019468.g003
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(Fig. 5B).
Discussion
The biological role of CDKs was previously thought to be
limited to regulating cell proliferation. However, recent findings
suggest that CDKs are key regulators of non-proliferative cellular
functions such as cell mobility and survival [8,9,10,11]. The
molecular mechanisms by which CDKs mediate these functions
are unknown. We show here that CDK4 directly phosphorylated
c-Jun following mouse and human immune cell stimulation,
leading to activation of the transcription factor AP-1 and
enhanced production of AP-1 dependent cytokines. This is in
direct support of a recent publication by Cho et. al. indicating that
c-Jun is a target for CDK3 and therefore a regulator of AP-1
function necessary for proliferation and transformation [24]. In
addition to this, data presented here using non-dividing BMDCs,
indicate that CDK4 activity and AP-1 regulatory mechanism(s) are
independent of cell proliferation.
In addition to identifying a new CDK4 substrate, these findings
provide insights into the role of CDKs in non-proliferative cell
functions, and highlight implications for the pharmacological
effects of therapeutic CDK inhibition. Currently, CDK inhibitors
are being tested as therapies for autoimmune disease and cancer
[17,33,34]. Alvocidib, a CDK inhibitor and potential anti-cancer
drug, abrogates experimental arthritis in mouse models [17]. The
original explanation of Alvocidib’s effect was blocking synovial
fibroblast proliferation. While the drug does have this effect, there
may be additional biological effects of CDK inhibitors in arthritis.
Our results indicate that CDK inhibitors may also reduce the
production of IL-6 and IL-1 by reducing the activity of AP-1.
Previous studies report that neutralizing antibody therapy against
IL-6 reduces arthritis scores and severity in both mice and humans
[35,36,37,38]. With regards to cancer immunotherapy, the
blockade of IL-6 has been shown to reduce tumor growth in
myeloma models [39]. Our data suggest that the use of CDK
inhibitors may block production of IL-6 and therefore be of benefit
to myeloma patients. However, the use of CDK inhibitors to treat
some cancers may inhibit anti-tumor immune responses and
therefore counter some of the effects of this drug treatment.
Our results focus on CDK4’s ability to phosphorylate c-Jun, but
other CDK family members may also regulate AP-1 through a
similar mechanism to that demonstrated for CDK4. In addition to
the partially redundant nature of CDKs, the common SAP kinase-
phosphorylated residues of c-Jun (Ser63, 73 and Thr91 and 93)
Fig. 4. CDK4 activity in non-dividing cells. A) Mixed myeloid cells expanded from bone marrow of C57Bl/6 mice were stained with CFSE prior to
stimulation with the TLR7 agonist R848. After 48 and 72 hours cells were fixed and stained for phosphoryated Rb protein on the CDK4 specific site Ser
780. Cells in gate M1 are CFSE high and represent non-dividing cells. The percentage of cells within this gate remained approximately 26% for three
days. Cells in gates M2 and M3 are CFSE low and represent cells that have gone through 1 or more than 1 division respectively. From day 2 to day 3
the % of M2 cells has decreased while the percent of cells in M3 has increased indicating ongoing proliferation. B) A histogram of MFI for phospho-Rb
from each of the M gates indicates phosphorylation of Rb protein in all stages of division (line represents MFI of non-stimulated cells). C) Histogram of
cells from M1 gate stained for phospho-Rb protein after 48 hours of R848 stimulation. Peak 1 is the isotype control of stimulated cells, peak 2 is the
p-Rb staining of non-stimulated cells, and peak 3 is the p-Rb staining of R848 stimulated cells. These data are representative of two individual
experiments.
doi:10.1371/journal.pone.0019468.g004
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indicating potential for other CDKs to phosphorylate c-Jun. This
may be why Wt cells treated with pan-CDK inhibitors exhibited a
more complete inhibition of c-Jun phosphorylation than did
CDK4 deficient cells (Figs. 2 and 4). The ability of additional
CDKs to phosphorylate cJun and regulate AP-1 is currently being
investigated, and we are searching for other CDK targets.
Intriguingly, other AP-1 subunits (JunD, B and cFos) contain
weak CDK consensus sequences and therefore may be phosphor-
ylated/regulated by CDKs, thus further expanding the known
functions of CDKs.
Our findings indicate that CDK4 can regulate the function of
AP-1 through the direct phosphorylation of c-Jun, and therefore
potentially regulates a number of cellular functions independent of
replication. This newly described molecular interaction of a CDK
may have important implications for treatment of autoimmune
and inflammatory diseases, as well as suggesting new properties
relevant to the use of CDK inhibitors as anti-cancer reagents.
Materials and Methods
Reagents
CDK inhibitors (SU9516, Fascaplysin, and CDK4 inhibitor -
CINK) and JNK inhibitor VIII were purchased from Calbiochem
(San Diego, CA). The construct encoding constitutively active
human CDK4 (CDK4-R24C) was subcloned from the pBABE-
CDK4-R24C construct (a generous gift from Dr. A. Kingelhutz,
The University of Iowa, Iowa City, IA) into the popRSV.neo
Fig. 5. Phosphorylation of cJun by cellular CDK4. A) Purified recombinant CDK4:cyclinD complex was reacted with cJun and GSK GST fusion
proteins to determine specificity of phosphorylation by CDK4. Western blotting with phospho-specific Abs was used to monitor the phosphorylation
of the GST-fusion proteins. These data are representative of 3 separate experiments. B) CDK4 was immunoprecipitated from differentially stimulatedB
lymphocytes and reacted with GST-cJun fusion protein as described in Methods. The presence of cyclin D2 and phosphorylation of c-Jun was
analyzed by Western Blot using anti-Ser 73 phospho-cJun Abs. Blotting against CDK4 was used as a loading control. Quantitative analysis of
chemiluminescent band development enabled comparison of relative protein amounts between treatments (bar graphs). These data are
representative of 2 separate experiments.
doi:10.1371/journal.pone.0019468.g005
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the template for production of the CDK4 kinase dead mutant,
made by altering aspartic acid 158 to asparagine using a point
mutagenesis kit from Stratagene (Cedar Creek, TX) [42].
Antibodies (Abs) used for Western blots, intracellular cytokine
staining and immunoprecipitations were as follows: anti phospho-
c-Jun Ser73 Abs were purchased from either Upstate Biotechnol-
ogy (Lake Placid, NY) or Biosource (Carlsbad, CA). The anti-
phospho p38, total p38, phospho-JNK, total ERK 1/2, phospho-
Retinoblastoma protein (Ser 780), and GST Abs were purchased
from Cell Signaling Technologies (Beverly, MA). Abs against
phospho-ERK 1/2 were purchased from Biosource and the Abs
against total JNK, CDK4, cyclin D2, cyclin D1, CDK6 and
CDK2 were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). Antibodies used for flow cytometric analysis of DCs
(anti-CD11c and CD86) were purchased from eBioscience (San
Diego, CA). Anti-mouse IL-6 mAbs (MP5-20F3 and MP5-32C11,
biotin-conjugated) used for ELISA were also obtained from
eBioscience. Multiplex cytokine assay (mouse 20-plex) was
purchased from Biosource and used according to manufacturer’s
instructions.
Enzymatically active, purified CDK complexes were purchased
from Calbiochem. Fusion proteins c-Jun (residues 1–79)-GST and
GSK-3a-GST were purchased from Upstate Biotechnology and
BioVision (Mountain View, CA) respectively. The anti-mCD40
agonistic antibody 1C10 was purified from a hybridoma kindly
provided by Dr. Frances Lund (University of Rochester School of
Medicine, Rochester, NY). The stimulatory TLR7 ligand R848
was obtained from Alexis Biochemicals (San Diego, CA). CD154-
expressing Hi5 insect cells have previously been described [16].
Cells
Hi5 insect cells expressing CD154 have been previously
described [43]. Primary small dense (resting) splenic B lympho-
cytes were harvested from C57Bl/6 mice by Percoll gradient
centrifugation as previously described [44]. Purity was monitored
by flow cytometry with anti-CD19 mAb (eBioscience). Purity of
cells used was .92%. Human peripheral B cells were isolated
using a negative isolation kit (StemCell Technologies, Vancouver,
British Columbia) according to manufacturer’s instructions. Purity
of cells was .90%. Stimulation of cells through CD40 used either
Hi5 insect cells expressing the CD40 ligand (CD154) at a ratio of
1:5 Hi5 to immune cell, or using anti-CD40 monoclonal Ab,
1C10. Bone marrow derived dendritic cells (BMDCs) were
expanded and matured as previously described [45]. Unlike B
cells, BMDCs stimulated via CD40 did not respond with easily
detectable cJun phosphorylation or IL-6 production, so for these
cells, TLR stimulation alone was used. Bone marrow samples from
CDK4 deficient mice and littermate controls were kind gifts from
Dr. L. Schnapp, University of Washington, Seattle, WA and Dr.
H. Kiyokawa, University of Illinois College of Medicine, Chicago,
IL. Human myeloid cells were isolated and expanded from
peripheral blood (obtained from the DeGowin Blood Center at
The U of Iowa) as previously described [46]. Mice were used in
accordance with VAMC Animal Use guidelines.
Western blots
Cells lysates were prepared as previously described [16] and
separated using 10% SDS-polyacrylamide gels. Proteins were then
transferred onto PVDF membranes, and analyzed by Western blot
as previously described [16]. Peroxidase labeled secondary Abs
were visualized using the chemiluminescent detection reagent
West Pico peroxidase substrate (Pierce, Rockford, IL) and the
luminescence measured using a Fujifilm LAS-1000 imaging system
(Fujifilm Medical Systems, Ltd., Stanford, CT). Chemilumines-
cence was subsequently quantified using ImageGauge software
(FujiFilm).
IL-6 ELISA
Cells were treated as described with R848, CD154-expressing
or Wt Hi5 insect cells and/or chemical inhibitors (JNK VIII, and/
or CDK inhibitors). Chemical inhibitors were added 30 minutes
prior to stimulation and used at concentrations that did not
decrease cell viability, as monitored by detection of subdiploid
DNA using propidium iodide staining and flow cytometric analysis
[47]. Cell free supernatants were collected and quantitative ELISA
for IL-6 (eBioscience) was performed according to the manufac-
turer’s recommended protocol.
Luciferase assay
293T cells at 80% confluence were transfected in 2 ml cultures
of a 6 well plate with increasing amounts of a plasmid encoding
kinase dead CDK4, together with murine TLR7 (0.5 ug of
plasmid) and an AP-1 driven luciferase reporter plasmid. The
transfection utilized the reagent Lipofectamine (Invitrogen,
Carlsbad, CA) in accordance with manufacturer’s instructions.
Empty pRSV.neo vector plasmid was added to equalize the total
amount of transfected DNA. 24 hours after transfection, cells were
harvested from the 6 well plate, washed in growth medium, and
plated at 1610
5 cells per well in a 48 well plate. Cells were then
treated with medium or the TLR7 agonist R848 (1 ug/ml) for
20 hours and the relative amounts of luciferase activity were
measured using a dual reporter kit according to manufacturer’s
instructions (Promega, Madison, WI).
Proliferation measurements and intracellular staining for
phospho-Rb
Fully differentiated BMDCs were expanded as described [45]
and stained with CFSE (Molecular Probes – Eugene, Oregon) as
per the manufacturer’s instruction. Upon mitogenic stimulation,
the decrease in CFSE as it is portioned into daughter cells is
indicative of cellular division. Cells were stimulated as described
and monitored for division by flow cytometry. Partially differen-
tiated myeloid cells were expanded by culturing bone marrow cells
in GMCSF and IL-4 as described for BMDCs for 48 hours. After
48 hours, cells were stained with CFSE and stimulated with R848
for 48 and 72 hours. Cells were then fixed and permiablized using
methanol as previously described [48]. Cells were then stained
using an antibody against pRb protein or isotype control
antibodies (Cell Signaling Technologies) followed by a goat anti-
rabbit antibody labeled with APC –fluorochrome (Molecular
Probes). Cells that retained the same level of CFSE over the course
of three days were considered non-dividing. Flow cytometry was
performed on an ACCURI cytometer.
Immunoprecipitations (IP) and kinase assays
Freshly isolated resting B cells (2610
6 cells) were stimulated with
R848 (1 ug/ml) and CD154-expressing Hi5 insect cells or Hi5
cells without CD154 expression for 5 hours. Cells were then
pelleted by centrifugation (2 minutes at 500 x g) and resuspended
in 0.5 ml lysis buffer (50 mM HEPES, pH 7.3, 150 mM NaCl,
1 mM EDTA, 2.5 mM EGTA, 10 mM beta-glycerophosphate,
0.1 mM sodium orthovanadate, 0.1% Tween-20, and 10%
glycerol, with 0.1 mM PMSF, 1 mM DTT 1 mM NaF added
just before use). Cells were incubated at 4uC for 30 minutes. Anti-
CDK4 Ab (10 ug/ml) and 20 ul of protein A-Sepharose were
added to the cell lysates, which were rotated at 4uC for 2 hours. IP
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buffer (50 mM HEPES, pH 8.0, 10 mM MgCl2). The complexes
were then resuspended in 30 ul kinase buffer. 1 ul of 100 mM
ATP and 0.5 ug c-Jun -GST fusion protein were added to IP
suspensions. Kinase assays using purified CDK complexes were
performed using a reaction mixture of 0.2 ug kinase complex or
PKA, 1 ul of 100 mM ATP, and 0.5 ug GST fusion protein
diluted to a final volume of 35 ul with kinase buffer. Kinase
reactions proceeded at 30uC for 20 minutes with shaking
(1000 rpm on a heated shaker block). Reactions were stopped by
the addition of 12 ul of 4X SDS treatment buffer. The samples
were heated to 95uC for 10 minutes and subjected to Western
blotting.
Supporting Information
Fig. S1 Dendritic cells from CDK4 deficient mice show
mature phenotype. BMDCs were isolated and expanded as
described in the [material and methods]. Cells were then
stimulated with R-848 (1 ug/ml) for 24 hours and stained for
expression of A) CD11c, a DC marker and B) CD86, an activation
marker.
(TIF)
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